Highlights Newsletter 1

This newsletter presents you the following key sessions:

1. Olaparib plus abiraterone as first-line therapy for patients with metastatic castration-resistant prostate
    cancer

2. Sacituzumab govitecan plus pembrolizumab in patients with metastatic urothelial cancer progressing
    after platinum-based regimens

3. Promising antitumour activity with neoadjuvant enfortumab vedotin in cisplatin-ineligible muscle
    invasive bladder cancer

4. Adding darolutamide to docetaxel and androgen deprivation therapy significantly prolongs the survival
    of patients with metastatic hormone sensitive prostate cancer

5. Continued survival and quality of life benefit of cabozantinib-nivolumab over sunitinib as first-line
    treatment of advanced clear-cell renal cell carcinoma